Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Albeir Mousa

Emergency Medicine Charleston, WV Medical Doctor

NPI 1902831779 CMS profile 312737

3200 MacCorkle Avenue Se, Camc Vascular Center Of Excellence, Charleston, WV 25304

Open in the dashboard

General payments

$12,121

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Albeir Mousa of Charleston, WV is reported in the CMS Open Payments database as having received $12,121 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $116 4
2024 General $6,357 11
2023 General $2,078 26
2022 General $602 11
2021 General $605 6
2020 General $80 5
2019 General $2,282 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albeir Mousa
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Albeir Mousa were reported at $116. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Albeir Mousa Emergency Medicine median Middle half National median
2019 $2,282 $51 $18–$128 $163
2020 $80 $29 $16–$99 $114
2021 $605 $40 $18–$124 $132
2022 $602 $49 $20–$134 $149
2023 $2,078 $51 $22–$142 $160
2024 $6,357 $52 $22–$150 $164
2025 $116 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $6,280 6 payments
  2. W. L. Gore & Associates, Inc. $2,189 19 payments
  3. Silk Road Medical, Inc. $1,620 16 payments
  4. Bard Peripheral Vascular, Inc. $653 10 payments
  5. Organogenesis Inc. $304 9 payments
  6. Abbott Laboratories $194 2 payments
  7. Shockwave Medical, Inc $154 2 payments
  8. Cardiovascular Systems Inc. $149 3 payments
  9. Medtronic, Inc. $126 1 payment
  10. Maquet Cardiovascular U.S. Sales, L.L.C. $112 3 payments
  11. Other $342 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $4,800 1 payment
  2. Travel and Lodging $3,749 10 payments
  3. Food and Beverage $3,522 77 payments
  4. Education $51 3 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $1,084 7 payments
  2. ENROUTE Transcarotid Stent System $1,084 7 payments
  3. ENHANCE Transcarotid Peripheral Access Kit Carotid Artery Disease $1,084 7 payments
  4. ENROUTE 0.014 Guidewire $1,084 7 payments
  5. GORE TAG Thoracic Endoprosthesis $907 1 payment
  6. GORE TAG Thoracic Branch Endoprosthesis $690 3 payments
  7. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $536 9 payments
  8. ENROUTE Transcarotid Stent $536 9 payments
  9. ENHANCE Transcarotid Peripheral Access Kit Cardiology/Vascular Diseases $361 3 payments
  10. ENROUTE .014 Guidewire $361 3 payments
  11. Other $2,182 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

76

Median for Emergency Medicine: 88

Drug cost

$599

Median for Emergency Medicine: $590

Branded share of claims

59.2%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 33 $371
Cephalexin Generic 18 $91
Doxycycline Hyclate Generic 13 $81
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 117 billing codes

Paid by Medicare

$84,962

Medicare's payments for the services billed

Medicare patients

469

Average age 74

Services billed

975

247 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 52%
Diabetes 45%
Chronic kidney disease 42%
COPD 38%
Depression 32%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record